Physician profile
Michael M Reader
NPI 1629236260
$37,718.66
in general payments reported to CMS, 2019-2025
12 companies · $4,664 in 2025
The $4,664 reported for 2025 was more than what 90% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2021: $2,517 · 2022: $1,461 · 2023: $22K · 2024: $6,631 · 2025: $4,664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $28K · Travel and Lodging: $3,366 · Food and Beverage: $2,424 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $27,650.00 |
| Travel and Lodging | $3,366.04 |
| Food and Beverage | $2,424.41 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $32,488.34 | 2022-2025 | Davinci Xi, Da Vinci Surgical System |
| Allergan, INC. | $2,550.52 | 2019-2022 | |
| Davol INC. | $1,884.35 | 2019-2025 | Phasix Mesh |
| Dilon Technologies, INC. | $167.97 | 2025 | Hemoblast Bellows |
| Baxter Healthcare | $143.42 | 2025 | Perclot |
| Ethicon INC. | $140.65 | 2024 | |
| Tela Bio, INC. | $111.27 | 2021-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Becton, Dickinson and Company | $87.90 | 2023 | Phasix Mesh |
| Abbvie INC. | $80.08 | 2024-2025 | |
| Ethicon US, LLC | $22.90 | 2022 | |
| Aroa Biosurgery Incorporated | $22.29 | 2024 | |
| Medical Device Business Services, INC. | $18.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Reader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.